A Phase 3 Randomized, Open-Label Study Comparing Pexa Vec (Vaccinia GM CSF / Thymidine Kinase-Deactivated Virus) Followed by Sorafenib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC) Without Prior Systemic Therapy
Phase of Trial: Phase III
Latest Information Update: 14 Aug 2018
At a glance
- Drugs Pexastimogene devacirepvec (Primary) ; Sorafenib
- Indications Liver cancer
- Focus Registrational; Therapeutic Use
- Acronyms PHOCUS
- Sponsors SillaJen Biotherapeutics
- 13 Jan 2018 This trial was Discontinued in Poland, according to European Clinical Trials Database.
- 02 Jan 2018 According to a GC Pharma media release, Green Cross Corporation rebrands itself to GC Pharma.
- 04 Dec 2017 Planned primary completion date changed from 1 Oct 2017 to 1 Oct 2018.